Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial. J of Skin. 2022;6(6):s62. doi:10.25251/skin.6.supp.62